BALTIMORE - The Centers for Medicare & Medicaid Services issued final regulatory rule CMS-4215-F on Nov. 5, establishing a $2,400 out-of-pocket cap for Medicare Part D prescription drugs in 2027. Health administrators confirmed the federal regulation formally codifies drug price negotiation standards for 2029 and beyond across 40 selected prescription medications.
What happened?
Federal health regulators published administrative standards on Nov. 5 governing prescription drug affordability across insurance plans. Under the 2027 Part D framework, annual out-of-pocket spending for seniors increases by $300 from $2,100 in 2026 to $2,400, while the maximum plan deductible is capped at $700. Patients who reach the $2,400 threshold transition into catastrophic coverage, eliminating copayments for covered specialty medications through year-end. The rule also codifies manufacturer submission deadlines.
Why does it matter?
The regulatory codification represents a crucial transition from temporary guidance under the Inflation Reduction Act to permanent federal administrative law. Patient groups welcomed financial predictability for individuals dependent on oral chemotherapy regimens costing tens of thousands of dollars. Addressing finalized regulations on Nov. 5, federal administrators at CMS confirmed that Medicare Part D will ensure beneficiaries pay no more than $2,400 out of pocket for covered drugs in 2027. Advocates urged seniors to review plan formularies before open enrollment concludes.
What happens next?
Pharmaceutical manufacturers seeking biosimilar negotiation delay exemptions must submit formal documentation via the CMS Health Plan Management System by Dec. 10. The annual Medicare open enrollment period for calendar year 2027 coverage will officially close nationwide on Dec. 7. Negotiated maximum fair prices for the second tranche of 15 selected drugs will take effect on Jan. 1, 2027.
